Patients with Diffuse Large B-Cell Lymphoma, we need your help!
If you are a patient with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) and have been treated with Tafasitamab (Minjuvi), you can help by completing our survey.
Lymphoma Canada is preparing a submission for Canada’s Drug Agency (CDA). This survey provides us with the patient input required for the submission. CDA uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
The therapy that will soon be reviewed by the CDA is:
- Tafasitamab (Minjuvi) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a DLBCL patient who has not received this therapy.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
It should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
